

Supplementary Table 1 Association between HLA-DQA1*05 alleles and development of immunogenicity to infliximab

HLA	Anti-Infliximab Ab (-) (<i>n</i> = 19)	Anti-Infliximab Ab (+) (<i>n</i> = 19)	<i>P</i> value
HLA-DQA1*05:01:01	15.8	26.3	0.693
HLA-DQA1*05:03:01	10.5	5.3	1.000
HLA-DQA1*05:05:01	10.5	26.3	0.405

Analyzed according to Fisher's exact test.

Supplementary Table 2 Association between HLA-DQA1*05 alleles and development of immunogenicity to adalimumab

HLA	Anti-adalimumab Ab (-) (<i>n</i> = 17)	Anti-adalimumab Ab (+) (<i>n</i> = 3)	<i>P</i> value
HLA-DQA1*05:01:01	17.6	0	1.000
HLA-DQA1*05:03:01	0	0	
HLA-DQA1*05:05:01	47	66.7	1.000

Analyzed according to Fisher's exact test.

Supplementary Table 3 Frequency of IBD-associated HLA alleles in Taiwanese patients with IBD and the general population

HLA allele	IBD	Control	<i>P</i> value
B*15:02:01	7.4	3.7	0.015
B*46:01:01	15.8	10.5	0.026
DQA1*05:05:01	16.3	10.5	0.014
DRB3*01:01:02	20.9	10.1	< 0.001
DRB3*03:01:01	3.4	8.9	0.022
DRB4*01:02	39.5	0.9	< 0.001
DRB4*01:03:01	48.9	77.6	< 0.001
DRB4*01:03:02	10.0	19.6	0.002
DRB5*01:01:01	64.1	81.1	< 0.001
DRB5*02:02:01	31.0	3.7	< 0.001
C*07:04:01	2.6	0.6	0.011
C*12:02:02	1.1	4.0	0.044
DRB1*04:03:01	0.5	3.5	0.029
DPB1*19:01:01	3.2	1.2	0.038
DQA1*01:05:01	2.1	0.6	0.044
DQB1*06:03:01	2.1	0.6	0.041
DRB1*10:01:01	2.1	0.6	0.041
DRB1*13:01:01	2.1	0.6	0.049

Supplementary Table 4 Association between non-genetic factors and immunogenicity

	ADA (-) (<i>n</i> = 36)	ADA (+) (<i>n</i> = 22)	<i>P</i> value
Age	39.4 ± 12.7	37.5 ± 14.4	0.932
Gender (man)	27 (75.0)	16 (72.7)	0.848
Immunomodulators			0.461
Thiopurine	29 (80.6)	19 (90.5)	
Methotrexate	7 (19.4)	2 (9.5)	

ADA: Anti-drug antibody; MTX: Methotrexate.